A recent trial has shown that a single dose of the monoclonal antibody clesrovimab reduced the incidence of RSV-associated lower respiratory infection and RSV-associated hospitalisation in healthy preterm and full-term infants.
Clesrovimab demonstrated 60% efficacy in reducing medically attended RSV-associated lower respiratory infection and 84% efficacy in reducing RSV-associated hospitalisation. The adverse-event profile of clesrovimab was similar to that of placebo. The authors note that rare serious adverse events may not be detected in a trial of this size (3632 infants).
Read the paper in full: NEJM: Clesrovimab for prevention of RSV disease in healthy infants
Read more about respiratory syncytial virus (RSV) at MVEC: RSV